BRAF and thyroid cancer: Cheng et al. also demonstrated that combination treatment of thyroid cancer cells with vorinostat and vemurafenib, a BRAF inhibitor, synergistically induced NIS expression and localization to the cell membrane and RAI uptake (Table 2) 19.